Biogen Inc (BIIB)

Industry Drug Manufacturers - General


This stock can be held in an Investment ISA and an Investment Account
Sell

$124.04

Buy

$124.16

arrow-up$5.92 (+5.01%)

Prices updated at 12 May 2025, 18:09 EDT
| Prices minimum 15 mins delay
|
Prices in USD

Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases.

Income statement

20232024
9,836m9,676m
7,302m7,366m
1,831m2,219m
18.6222.93
1,161m1,632m
2,039m2,830m
Sales, General and administrative2,550m2,404m
Interest expenses247m250m
Provision for income taxes135m274m
Operating expenses5,471m5,147m
Income before taxes1,297m1,906m
Net income available to common shareholders1,161m1,632m
8.0211.21
Net interest income30m-183m
Advertising and promotion--
Net investment income, net--
Realised capital gains (losses), net--
Total benefits, claims and expenses--
Earnings per share (diluted)7.9711.18
Free cash flow per share7.053412.1144
Book value/share99.9572112.2631
Debt equity ratio0.4857090.292038

Balance sheet

20232024
Current assets6,859m7,457m
Current liabilities3,434m5,529m
Total capital21,588m21,263m
Total debt7,338m6,630m
Total equity14,799m16,716m
Total non current liabilities--
Loans6,788m4,547m
Total assets26,845m28,049m
Total liabilities--
Cash and cash equivalents1,050m2,375m
Common stock145m146m

Cash flow

20232024
Cash at beginning of period3,419m1,050m
Cash dividends paid--
1,236m2,516m
Investments (gains) losses-4,101m-799m
1,050m2,375m
Net income--
1,547m2,876m
-311m-360m
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.